Edward Levine to Chemotherapy, Cancer, Regional Perfusion
This is a "connection" page, showing publications Edward Levine has written about Chemotherapy, Cancer, Regional Perfusion.
Connection Strength
10.689
-
Ali YM, Sweeney J, Shen P, Votanopoulos KI, McQuellon R, Duckworth K, Perry KC, Russell G, Levine EA. Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma. Ann Surg Oncol. 2020 Jan; 27(1):117-123.
Score: 0.590
-
Dodson RM, Kuncewitch M, Votanopoulos KI, Shen P, Levine EA. Techniques for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2018 Aug; 25(8):2152-2158.
Score: 0.540
-
Votanopoulos KI, Bartlett D, Moran B, Haroon CM, Russell G, Pingpank JF, Ramalingam L, Kandiah C, Chouliaras K, Shen P, Levine EA. PCI is Not Predictive of Survival After Complete CRS/HIPEC in Peritoneal Dissemination from High-Grade Appendiceal Primaries. Ann Surg Oncol. 2018 Mar; 25(3):674-678.
Score: 0.537
-
Votanopoulos KI, Russell G, Randle RW, Shen P, Stewart JH, Levine EA. Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol. 2015 Apr; 22(4):1274-9.
Score: 0.430
-
Levine EA, Stewart JH, Shen P, Russell GB, Loggie BL, Votanopoulos KI. Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg. 2014 Apr; 218(4):573-85.
Score: 0.406
-
Votanopoulos KI, Swords DS, Swett KR, Randle RW, Shen P, Stewart JH, Levine EA. Obesity and peritoneal surface disease: outcomes after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for appendiceal and colon primary tumors. Ann Surg Oncol. 2013 Nov; 20(12):3899-904.
Score: 0.393
-
Votanopoulos KI, Newman NA, Russell G, Ihemelandu C, Shen P, Stewart JH, Levine EA. Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol. 2013 Oct; 20(11):3497-503.
Score: 0.392
-
Ihemelandu CU, McQuellon R, Shen P, Stewart JH, Votanopoulos K, Levine EA. Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ann Surg Oncol. 2013 Oct; 20(11):3519-26.
Score: 0.392
-
Votanopoulos KI, Swett K, Blackham AU, Ihemelandu C, Shen P, Stewart JH, Levine EA. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from rectal cancer. Ann Surg Oncol. 2013 Apr; 20(4):1088-92.
Score: 0.384
-
Votanopoulos KI, Shen P, Stewart JH, Levine EA. Current status and future directions in appendiceal cancer with peritoneal dissemination. Surg Oncol Clin N Am. 2012 Oct; 21(4):599-609.
Score: 0.373
-
Newman NA, Votanopoulos KL, Stewart JH, Shen P, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer. Minerva Chir. 2012 Aug; 67(4):309-18.
Score: 0.369
-
Votanopoulos KI, Ihemelandu C, Shen P, Stewart JH, Russell GB, Levine EA. Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg. 2012 Sep; 215(3):412-7.
Score: 0.364
-
Krane LS, Kader AK, Levine EA. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis secondary to urachal adenocarcinoma. J Surg Oncol. 2012 Mar; 105(3):258-60.
Score: 0.346
-
Hill AR, McQuellon RP, Russell GB, Shen P, Stewart JH, Levine EA. Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol. 2011 Dec; 18(13):3673-9.
Score: 0.341
-
Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin. Ann Surg Oncol. 2010 Oct; 17(10):2720-7.
Score: 0.315
-
Shen P, Stewart JH, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: overview and rationale. Curr Probl Cancer. 2009 May-Jun; 33(3):125-41.
Score: 0.295
-
Shen P, Stewart JH, Levine EA. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer with peritoneal surface disease. Curr Probl Cancer. 2009 May-Jun; 33(3):154-67.
Score: 0.295
-
Shen P, Stewart JH, Levine EA. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: non-colorectal indications. Curr Probl Cancer. 2009 May-Jun; 33(3):168-93.
Score: 0.295
-
Stewart JH, Shen P, Levine EA. Intraperitoneal hyperthermic chemotherapy: an evolving paradigm for the treatment of peritoneal surface malignancies. Expert Rev Anticancer Ther. 2008 Nov; 8(11):1809-18.
Score: 0.285
-
Wood BC, Kleinpeter KP, Levine EA. Treatment of in-transit metastases from Merkel cell carcinoma with isolated hyperthermic limb perfusion. Am Surg. 2007 Dec; 73(12):1291-2.
Score: 0.267
-
McQuellon RP, Russell GB, Shen P, Stewart JH, Saunders W, Levine EA. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol. 2008 Jan; 15(1):125-33.
Score: 0.267
-
McQuellon RP, Danhauer SC, Russell GB, Shen P, Fenstermaker J, Stewart JH, Levine EA. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007 Mar; 14(3):1105-13.
Score: 0.251
-
Enomoto LM, Choudry MH, Bartlett DL, Totin L, Mann GN, Skitzki JJ, Perry KC, Votanopoulos KI, Levine EA, Shen P. Outcomes After Adjuvant Hyperthermic Intraperitoneal Chemotherapy for High-Risk Primary Appendiceal Neoplasms After Complete Resection. Ann Surg Oncol. 2020 Jan; 27(1):107-114.
Score: 0.150
-
Alzahrani NA, Valle SJ, Fisher OM, Sugarbaker PH, Yonemura Y, Glehen O, Goere D, Honore C, Brigand C, de Hingh I, Verwaal VJ, Deraco M, Baratti D, Kusamura S, Pocard M, Piso P, Maerz L, Marchal F, Moran B, Levine EA, Dumont F, Pezet D, Abboud K, Kozman MA, Liauw W, Morris DL. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi-institutional experience. J Surg Oncol. 2019 Mar; 119(3):336-346.
Score: 0.144
-
Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Ann Surg Oncol. 2018 Mar; 25(3):667-673.
Score: 0.134
-
Mercier F, Passot G, Villeneuve L, Levine EA, Yonemura Y, Goéré D, Sugarbaker PH, Marolho C, Bartlett DL, Glehen O. Peritoneal Carcinomatosis of Urachus Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An International Registry of 36 Patients. Ann Surg Oncol. 2018 Apr; 25(4):1094-1100.
Score: 0.134
-
Konstantinidis IT, Levine EA, Chouliaras K, Russell G, Shen P, Votanopoulos KI. Interval between cytoreductions as a marker of tumor biology in selecting patients for repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2017 Nov; 116(6):741-745.
Score: 0.129
-
Foster JM, Sleightholm R, Smith L, Ceelen W, Deraco M, Yildirim Y, Levine E, Muñoz-Casares C, Glehen O, Patel A, Esquivel J. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. J Surg Oncol. 2016 12; 114(7):779-784.
Score: 0.125
-
Schwarz L, Votanopoulos K, Morris D, Yonemura Y, Deraco M, Piso P, Moran B, Levine EA, Tuech JJ. Is the Combination of Distal Pancreatectomy and Cytoreductive Surgery With HIPEC Reasonable?: Results of an International Multicenter Study. Ann Surg. 2016 Feb; 263(2):369-75.
Score: 0.118
-
Mogal HD, Levine EA, Fino NF, Obiora C, Shen P, Stewart JH, Votanopoulos KI. Routine Admission to Intensive Care Unit After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy: Not Always a Requirement. Ann Surg Oncol. 2016 May; 23(5):1486-95.
Score: 0.116
-
Mogal HD, Levine EA, Russell G, Shen P, Stewart JH, Votanopoulos KI. Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries. Ann Surg Oncol. 2016 Feb; 23(2):534-8.
Score: 0.114
-
Randle RW, Ahmed S, Levine EA, Fino NF, Swett KR, Stewart JH, Shen P, Votanopoulos KI. Significance of diabetes on morbidity and mortality following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. J Surg Oncol. 2015 May; 111(6):740-5.
Score: 0.109
-
Randle RW, Levine EA, Clark CJ, Stewart JH, Shen P, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for gallbladder cancer: a retrospective review. Am Surg. 2014 Jul; 80(7):710-3.
Score: 0.105
-
Blackham AU, Russell GB, Stewart JH, Votanopoulos K, Levine EA, Shen P. Metastatic colorectal cancer: survival comparison of hepatic resection versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2014 Aug; 21(8):2667-74.
Score: 0.103
-
Votanopoulos KI, Randle RW, Craven B, Swett KR, Levine EA, Shen P, Stewart JH, Mirzazadeh M. Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014 Mar; 21(3):868-74.
Score: 0.101
-
Sun Y, Shen P, Stewart JH, Russell GB, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from small bowel adenocarcinoma. Am Surg. 2013 Jun; 79(6):644-8.
Score: 0.098
-
Parson EN, Lentz S, Russell G, Shen P, Levine EA, Stewart JH. Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg. 2011 Oct; 202(4):481-6.
Score: 0.084
-
Ortega-Deballon P, Glehen O, Levine E, Piso P, Sugarbaker PH, Hayes-Jordan A, Facy A, Bakrin N, Rat P. Childbearing after hyperthermic intraperitoneal chemotherapy: results from an international survey. Ann Surg Oncol. 2011 Aug; 18(8):2297-301.
Score: 0.083
-
Stewart JH, Levine EA, Shen P. The current role of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of appendiceal tumors. Curr Probl Cancer. 2009 May-Jun; 33(3):142-53.
Score: 0.074
-
McQuellon R, Gavazzi C, Piso P, Swain D, Levine E. Quality of life and nutritional assessment in peritoneal surface malignancy (PSM): recommendations for care. J Surg Oncol. 2008 Sep 15; 98(4):300-5.
Score: 0.071
-
Shen P, Thai K, Stewart JH, Howerton R, Loggie BW, Russell GB, Levine EA. Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol. 2008 Dec; 15(12):3422-32.
Score: 0.070
-
Stewart JH, Shen P, Russell G, Fenstermaker J, McWilliams L, Coldrun FM, Levine KE, Jones BT, Levine EA. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008 Aug; 15(8):2137-45.
Score: 0.069
-
McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003 Mar; 10(2):155-62.
Score: 0.048
-
Garland-Kledzik M, Uppal A, Naeini YB, Stern S, Erali R, Scholer AJ, Khader AM, Santamaria-Barria JA, Cummins-Perry K, Zhou Y, Votanopoulos KI, Shen P, Levine EA, Bilchik AJ. Prognostic Impact and Utility of Immunoprofiling in the Selection of Patients with Colorectal Peritoneal Carcinomatosis for Cytoreductive Surgery (CRS) and Heated Intraperitoneal Chemotherapy (HIPEC). J Gastrointest Surg. 2021 01; 25(1):233-240.
Score: 0.041
-
Moaven O, Su J, Jin G, Votanopoulos KI, Shen P, Mangieri C, O'Neill SS, Perry KC, Levine EA, Miller LD. Clinical Implications of Genetic Signatures in Appendiceal Cancer Patients with Incomplete Cytoreduction/HIPEC. Ann Surg Oncol. 2020 Dec; 27(13):5016-5023.
Score: 0.040
-
Forsythe SD, Sasikumar S, Moaven O, Sivakumar H, Shen P, Levine EA, Soker S, Skardal A, Votanopoulos KI. Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform. Ann Surg Oncol. 2020 Dec; 27(13):4950-4960.
Score: 0.040
-
Votanopoulos KI, Shen P, Stewart JH, Levine EA. Outcomes of Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients Older than 70 Years; Survival Benefit at Considerable Morbidity and Mortality: A Reply. Ann Surg Oncol. 2017 12; 24(Suppl 3):602.
Score: 0.033
-
Kusamura S, Moran BJ, Sugarbaker PH, Levine EA, Elias D, Baratti D, Morris DL, Sardi A, Glehen O, Deraco M. Multicentre study of the learning curve and surgical performance of cytoreductive surgery with intraperitoneal chemotherapy for pseudomyxoma peritonei. Br J Surg. 2014 Dec; 101(13):1758-65.
Score: 0.027
-
Bryan ML, Fitzgerald NC, Levine EA, Shen P, Stewart JH, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in sarcomatosis from gastrointestinal stromal tumor. Am Surg. 2014 Sep; 80(9):890-5.
Score: 0.027
-
Doud AN, Randle RW, Clark CJ, Levine EA, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Impact of distal pancreatectomy on outcomes of peritoneal surface disease treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015 May; 22(5):1645-50.
Score: 0.027
-
Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Peritoneal surface disease with synchronous hepatic involvement treated with Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2015 May; 22(5):1634-8.
Score: 0.027
-
Ahmed S, Levine EA, Randle RW, Swett KR, Shen P, Stewart JH, Votanopoulos KI. Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol. 2014 Dec; 21(13):4226-31.
Score: 0.026
-
Randle RW, Swett KR, Swords DS, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol. 2014 May; 21(5):1474-9.
Score: 0.025
-
Turaga K, Levine E, Barone R, Sticca R, Petrelli N, Lambert L, Nash G, Morse M, Adbel-Misih R, Alexander HR, Attiyeh F, Bartlett D, Bastidas A, Blazer T, Chu Q, Chung K, Dominguez-Parra L, Espat NJ, Foster J, Fournier K, Garcia R, Goodman M, Hanna N, Harrison L, Hoefer R, Holtzman M, Kane J, Labow D, Li B, Lowy A, Mansfield P, Ong E, Pameijer C, Pingpank J, Quinones M, Royal R, Salti G, Sardi A, Shen P, Skitzki J, Spellman J, Stewart J, Esquivel J. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol. 2014 May; 21(5):1501-5.
Score: 0.025
-
Randle RW, Swett KR, Shen P, Stewart JH, Levine EA, Votanopoulos KI. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in peritoneal sarcomatosis. Am Surg. 2013 Jun; 79(6):620-4.
Score: 0.024
-
Cao C, Yan TD, Morris DL, van der Speeten K, Laurberg S, Glehen O, Link K, Piso P, Tentes AA, Deraco M, Larsen SG, Kecmanovic D, Bayón LG, Melero JT, González-Moreno S, Mahteme H, Gertsch P, Moran B, Esquivel J, Alexander R, Levine EA, Sugarbaker PH. Prospective Registry On Mesothelioma Peritonei Treatment (PROMPT): study design and rationale. Tumori. 2012 Jan-Feb; 98(1):166-71.
Score: 0.022